US HHS Secretary RFK Jr. on autism, says we will have an answer for you

Commentary of this kind from a sitting health secretary is best read as signalling intent rather than policy, since remarks without a rulemaking docket, funding line, or published study behind them have historically faded quickly in the affected names. The transmission channel where such statements have mattered is the vaccine and paediatric-pharma complex, where perceived regulatory hostility has in past episodes widened the risk discount on manufacturers with exposure to childhood immunisation schedules, while names without that exposure tend to be unaffected. The distinction worth drawing is between a rhetorical commitment to find an answer and an actual administrative act: the former moves sentiment briefly, the latter, via advisory committee composition, schedule reviews, or liability questions, moves fundamentals. The secretary's prior form is a long public record of scepticism toward established vaccine science, so the market's starting assumption is adversarial rather than neutral. Follow-ons worth noting are any announcement of a study mandate, panel appointments, or CDC schedule review, which would convert rhetoric into process. Absent that, this is headline noise with a known directional lean but no mechanism yet.